New Study: Patients Unlikely to See Out-Of-Pocket Drug Savings from IRA
NEWS
Filter posts by:
New Report Provides Critical Context to Government Claims of IRA So-Called Drug Savings and Explores the Law’s True Impact on Patient Costs
Recognizing the Hatch-Waxman Act’s 40th Anniversary on Capitol Hill
We Work For Health Urges Senate HELP Committee to Reject Bills that Undermine IP and Patent Protections
Fact Checking the Inflation Reduction Act’s Real-World Impact and Consequences
Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem
Watch: California leaders highlight biopharma innovation, collaboration and policy progress
Don’t Throw Out 40 Years of Innovation by Dismantling IP Protections
Policymakers: Protect & Maximize U.S. Intellectual Property for Biopharma Innovation that Helps Patients
State-By-State Data Showcases Biopharma’s Impact on Local Economics and Innovation
Protecting the Drug Discovery Pipeline
We Work For Health Statement on IRA Medicare Price Setting Announcement
A Guide to Understanding the Administration’s Announcement on Medicare Drug Pricing
10 Reasons Biopharma Innovation Needs Strong IP Protections
Inflation Reduction Act Causes Medicare Part D Premiums To Increase Again
We Work For Health's Comments on IPAY 2027 draft guidance
New Research Shows Alarming Drop in Neurology Innovation Due To IRA’s Small Molecule ‘Pill Penalty’
New Report Demonstrates How the IRA’s “Pill Penalty” is Setting Back the Development of Non-Opioid Pain Medicine
We Work For Health Honors Rep. Scott Peters with Healthcare Leadership Innovation Award
As NIST Finalizes March-in Guidance, Innovation Community Continues to Convey Opposition
New Data Reveals Strong Economic Impact of Texas Biopharmaceutical Industry
The Inflation Reduction Act is Hurting Medicare Access and Increasing Patients’ Costs
CMS Finalizes Policy to Facilitate Faster Biosimilar Uptake but Follow-on Policies and Actions Still Needed
Statement by We Work For Health Executive Director Dan Leonard on World IP Day
Commonsense Policies Needed to Lower Healthcare Costs and Improve Patient Access While Protecting Drug Development Pipeline
Paths to Progress: Understanding Policy’s Broad Impact on US Leadership in Biopharma
Vendors Power America's Biopharmaceutical Industry
President Biden’s State of the Union Call for IRA Expansion Hurts Patients, Workers, and U.S. Leadership
House Reviews the ORPHAN Cures Act
Biden's Attempts to Lower Drug Costs Are Sabotaging Biosimilar Competition and Are Destined For Failure
Statement By We Work For Health on the Ensuring Pathways to Innovative Cures (EPIC) Act
The Biden administration should not support a WTO petition to strip IP protections from Covid-19 treatments
How American Patients Will Bear the Cost of Government Price Controls
The Bayh-Dole Act works. It’s not time to change it.
Biden Administration’s Threat to Pharmaceutical Innovation Endangers Lives
Biden's Bayh-Dole Act proposal misuses 'march-in rights'
Medicare prescription price controls will hurt seniors
Protect Future Discoveries By Rejecting The TRIPS Patent Waiver
International Association of Fire Fighters' General President Sends Letter to U.S. Secretary of Commerce Opposing World Trade Organization TRIPS Waiver
Breaking the Law That Led to 7,739 Patents and 1,000 Startups in 2022 Alone
A patent waiver is a bad deal for WA
Proposed IRA Expansion Would Cripple Biopharma, Lead to Fewer Drugs: Report
Biden Administration Policy Jeopardizes The System That Gave Us Gene Editing
Price Fixing Never Works
Don't let geopolitics erode America's research engine
New Study Reinforces That Expansion of IRA Price Setting Would Further Crush Patient Health, Innovative Treatments and U.S. Biopharma Jobs
President Biden’s domestic technology seizure plan
New patent proposal would kill innovation across industries
White House’s Drug Patent Plan Undercuts Research and Innovation